trial

Anticholinergic Deprescription in Schizophrenia

NCTId NCT06562608
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 105 (estimated)
Sponsored by Deepak K. Sarpal, M.D.
Primary completion 2028-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
105 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2025-02-01
Primary completion
2028-12-31
Eligibility
ALL · 40 Years · 70 Years

Interventions & indications

Drugs
Anticholinergic DeprescriptionNo Anticholinergic Deprescription

Sponsors

Deepak K. Sarpal, M.D.Lead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

1 total
Pittsburgh, United States

Facts & assertions

4 sourced
Enrollment
105
Phase
PHASE4
Primary Completion Date
2028-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Anticholinergic Deprescription
drug
No Anticholinergic Deprescription
drug
lead_sponsor
Deepak K. Sarpal, M.D.
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Deepak C D'Souza, M.D.
person